AU6569998A - Obesity protein formulations - Google Patents

Obesity protein formulations

Info

Publication number
AU6569998A
AU6569998A AU65699/98A AU6569998A AU6569998A AU 6569998 A AU6569998 A AU 6569998A AU 65699/98 A AU65699/98 A AU 65699/98A AU 6569998 A AU6569998 A AU 6569998A AU 6569998 A AU6569998 A AU 6569998A
Authority
AU
Australia
Prior art keywords
protein formulations
obesity protein
obesity
formulations
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU65699/98A
Inventor
Joseph V. Rinella Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU6569998A publication Critical patent/AU6569998A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU65699/98A 1997-03-20 1998-03-19 Obesity protein formulations Abandoned AU6569998A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4127297P 1997-03-20 1997-03-20
US60041272 1997-03-20
PCT/US1998/005415 WO1998041222A1 (en) 1997-03-20 1998-03-19 Obesity protein formulations

Publications (1)

Publication Number Publication Date
AU6569998A true AU6569998A (en) 1998-10-12

Family

ID=21915682

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65699/98A Abandoned AU6569998A (en) 1997-03-20 1998-03-19 Obesity protein formulations

Country Status (2)

Country Link
AU (1) AU6569998A (en)
WO (1) WO1998041222A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008087121A1 (en) * 2007-01-17 2008-07-24 Merz Pharma Gmbh & Co. Kgaa Use of a surfactant for the preparation of a formulation for the treatment of adipose dieseases
PT2621519T (en) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Leptin-abd fusion polypeptides with enhanced duration of action
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165981A (en) * 1995-03-07 2000-12-26 Dade Behring Inc. Stabilizing solutions for proteins and peptides
AU5539596A (en) * 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
AU6028396A (en) * 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method

Also Published As

Publication number Publication date
WO1998041222A1 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
AU6030398A (en) Human proteins
EG23685A (en) Activated protein c formulations
AU2434199A (en) Protein
AU6721696A (en) Cd44-like protein
AU1750997A (en) Obesity protein formulations
AU1705197A (en) Obesity protein formulations
AU9017598A (en) Human frezzled-like protein
AU2243997A (en) Obesity protein formulations
AU9105698A (en) Rab proteins
AU1747297A (en) Obesity protein formulations
AU1999999A (en) Contryphan peptides
AU6000698A (en) Proteins
AU6275098A (en) Novel h-rev 107-like protein
AU4849299A (en) Human emr1-like g protein coupled receptor
AU6569998A (en) Obesity protein formulations
AU8063298A (en) Human formin binding protein
AU6050198A (en) Novel human cystatin-like protein
AU4992099A (en) Human presenilin-associated protein
AU2593199A (en) Human smn-like protein
AU2659799A (en) Human receptor proteins
AU4151597A (en) Human dbi/acbp-like protein
AU4160597A (en) Protein formulations
AU7259898A (en) Human smt-3 like protein
AU9376598A (en) Human (act)va-orf4-like protein
AU9318798A (en) Ras-like protein